Durata Therapeutics (DRTX) announced that the company has received a Special Protocol Agreement (SPA) from the FDA on the design of its Phase 3 study of DALVANCE (dalbavancin) for injection using a 1500 mg single dose for the treatment of patients with community-acquired pneumonia requiring intravenous therapy.
DALVANCE is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. The study is designed to compare a 1500 mg single IV dose of dalbavancin with linezolid; patients randomized to linezolid can switch to oral therapy after an initial period of IV treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.